Clinical trials: Metastatic Gastrointestinal Cancer
Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate [ORR; Cohorts 1,2, 4,and 5] and…
- Conditions
- Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
- Trial name
- GOBLET (NCT07280377)
- Testing
- Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel
- Where
- 15 sites in Germany
- Volunteers
- 122 people
- Sponsor
- Oncolytics Biotech
Colorectal Carcinoma
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to patients with metastatic colorectal carcinoma.
- Trial name
- NCT02248805
- Testing
- MGD007
- Where
- 8 sites in United States
- Volunteers
- 95 people
- Sponsor
- MacroGenics
Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Hepatocellular Carcinoma
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and…
- Trial name
- NCT05440708
- Testing
- TTI-101, Pembrolizumab, Atezolizumab
- Where
- 21 sites in United States
- Volunteers
- 193 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Advanced or Metastatic Pancreatic Adenocarcinoma
Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine
A dose finding study in locally advanced and/or metastatic pancreatic cancer patients
- Trial name
- NCT00560963
- Testing
- everolimus
- Where
- 5 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Neoplasms
A Study for Participants With Pancreatic Cancer
The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study.
- Trial name
- NCT00839332
- Testing
- LY2603618, Gemcitabine
- Where
- 30 sites in United States, Germany and 4 more
- Volunteers
- 157 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Carcinoma, Colorectal
Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin…
- Trial name
- NCT01380600
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Jennerex Biotherapeutics
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
This study will assess the efficacy and safety of intermittent oral Xeloda administration in combination with irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer.
- Trial name
- NCT00048139
- Testing
- Irinotecan, capecitabine [Xeloda]
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma…
- Trial name
- NCT04704934
- Testing
- Trastuzumab deruxtecan, Ramucirumab, Paclitaxel
- Where
- 156 sites in Argentina, Belgium and 22 more
- Volunteers
- 490 people
- Sponsor
- Daiichi Sankyo
Stomach Neoplasms
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen])…
- Trial name
- NCT03675737
- Testing
- Pembrolizumab, Cisplatin, 5-fluorouracil
- Where
- 215 sites in United States, Argentina and 31 more
- Volunteers
- 1,579 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line
This is a national, multicentric, prospective, observational trial. The decision to prescribe FOLFOX or FOLFIRI plus panitumumab or FOLFOX or FOLFIRI plus cetuximab must have been freely taken by the clinician prior to the study…
- Trial name
- SILQ (NCT02624895)
- Where
- 31 sites in Italy
- Volunteers
- 296 people
- Sponsor
- Amgen
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer
This study is conducted in patients with advanced metastatic gastric cancer including gastroesophageal junction cancer. This study includes two arms: A and B.
- Trial name
- NCT05246982
- Testing
- HLX07+HLX10+oxaliplatin+capecitabine, HLX07
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Henlius Biotech
BRAF V600E-mutant Metastatic Colorectal Cancer
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in…
- Trial name
- BEACON CRC (NCT02928224)
- Testing
- Encorafenib, Binimetinib, Cetuximab
- Where
- 418 sites in United States, Argentina and 25 more
- Volunteers
- 702 people
- Sponsor
- Pfizer
Colorectal Neoplasms
Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
This randomized, open-label, multicenter study will evaluate the efficacy and safety of folinic acid (leucovorin), 5-fluorouracil (5-FU), oxaliplatin, and irinotecan (FOLFOXIRI) / bevacizumab regimens (concurrent and sequential)…
- Trial name
- STEAM (NCT01765582)
- Testing
- 5-fluorouracil, bevacizumab, capecitabine
- Where
- 45 sites in United States
- Volunteers
- 280 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
To assess the efficacy and safety of the combination of CPGJ602 and chemotherapy in subjects with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.
- Trial name
- NCT04466254
- Testing
- CPGJ602, cetuximab
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Pancreatic Neoplasms
Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of pancreatic cancer.
- Trial name
- NCT00041639
- Testing
- hMN14 (labetuzumab)
- Where
- 10 sites in United States, Germany and 2 more
- Volunteers
- 75 people
- Sponsor
- Gilead Sciences
Neoplasms, Breast, Neoplasms, Lung
Study of ESG401 in Adults With Solid Tumors
The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer.
- Conditions
- Neoplasms, Breast, Neoplasms, Lung, Neoplasms,Colorectal, Neoplasms, Bladder
- Trial name
- NCT04892342
- Testing
- ESG401
- Where
- 3 sites in China
- Volunteers
- 156 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
Colorectal Cancer
A Study of Picoplatin in Colorectal Cancer
Colorectal cancer is a type of cancer that begins in the large intestine (colon) or the rectum (end of the colon). Several drugs are often given in combination to treat colorectal cancer.
- Trial name
- NCT00478946
- Testing
- (FOLPI) Picoplatin with 5-FU and Leucovorin, FOLPI, FOLFOX
- Where
- 16 sites in Russia
- Volunteers
- 43 people
- Sponsor
- Poniard Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.